As an innovative and dynamic contract research organization (CRO) InnoSer supports the preclinical pipeline from its facilities in Belgium and the Netherlands. Founded in 2012, our in-depth expertise allows us to provide customized and streamlined early drug development options with well-characterized and translational research models. Our services are designed with personalized tailoring in mind, supported by innovative technical capabilities and executed in close collaboration with our partners.

Our Focus

We understand that nonclinical research is a complex, lengthy and expensive process that requires knowledge, expertise and a high degree of organization. We also acknowledge that subcontracting this vital part of your business’ success is no small feat. As such, we’re deeply committed to your success.

Our current operations focus within the later stages of drug-discovery and early preclinical stage. With in vitro and in vivo disease models available for nephrology, immuno-oncology, neurology and cardiometabolic research, we guide our clients through the drug development pipeline using a combination of in house expertise and disease specific models. We support our clients in identifying new drugs or applications, characterizing their pharmacological characteristics, and conducting safety and efficacy testing within relevant biological research models. InnoSer enhances these offerings by providing state-of-the-art imaging and digital pathology options, along with facility management and support services including colony management, cryopreservation, and sanitation/rederivation.

We embrace innovation to meet the needs of our partners and the evolving industry. With a focus on proactive problem solving, we have proven ourselves to be a flexible and professional partner in the market. Together we create a smart road to better health.

Jan Bartels, Managing Director at InnoSer - Video